Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Common Equity (2016 - 2025)

United Therapeutics' Common Equity history spans 17 years, with the latest figure at $7.1 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 10.12% year-over-year to $7.1 billion; the TTM value through Dec 2025 reached $7.1 billion, up 10.12%, while the annual FY2025 figure was $7.1 billion, 10.12% up from the prior year.
  • Common Equity for Q4 2025 was $7.1 billion at United Therapeutics, up from $6.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $7.2 billion in Q2 2025 and bottomed at $3.4 billion in Q1 2021.
  • The 5-year median for Common Equity is $5.4 billion (2023), against an average of $5.3 billion.
  • The largest annual shift saw Common Equity rose 4.19% in 2024 before it grew 27.52% in 2025.
  • A 5-year view of Common Equity shows it stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then increased by 24.77% to $6.0 billion in 2023, then rose by 7.67% to $6.4 billion in 2024, then rose by 10.12% to $7.1 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Common Equity are $7.1 billion (Q4 2025), $6.6 billion (Q3 2025), and $7.2 billion (Q2 2025).